No Direct Evidence Comparing Sleep Onset Speed Between Daridorexant and Lemborexant
There is no head-to-head trial directly comparing daridorexant to lemborexant for sleep onset speed, but indirect evidence suggests lemborexant may have a slight advantage for sleep onset latency specifically.
What the Evidence Shows
Lemborexant's Sleep Onset Profile
The most recent indirect comparison found that lemborexant 5 mg and 10 mg were most effective for subjective sleep onset time (sTSO) reduction among all dual orexin receptor antagonists (DORAs) 1. This 2023 Bayesian network analysis demonstrated lemborexant had superior performance specifically for the sleep onset parameter when compared indirectly with other DORAs including daridorexant.
An independent 2023 analysis using number needed to treat (NNT) methodology found that lemborexant 5 mg and 10 mg had clinically relevant therapeutic effect sizes with most NNT values versus placebo < 10 for sleep onset and maintenance outcomes 2. This suggests robust efficacy for helping patients fall asleep faster.
Daridorexant's Sleep Onset Profile
For daridorexant, the evidence shows:
- Moderate efficacy for latency to persistent sleep (LPS), particularly at higher doses (10 mg and 50 mg) 1
- The 2023 NNT analysis found that daridorexant 25-mg and 50-mg doses pooled resulted in most NNT values versus placebo ≥ 10, suggesting less robust efficacy compared to lemborexant 2
- A 2026 meta-analysis confirmed daridorexant was superior to placebo for LPS during initial treatment (1-2 days) and at 1 month, with the 25 mg dose maintaining effectiveness at 3 months 3
Key Nuances in the Comparison
Different Strengths for Different Insomnia Types
The 2025 comprehensive analysis provides the most clinically useful guidance: For insomnia characterized by difficulty falling asleep, lemborexant 10 mg/day is recommended as a priority 4. This same analysis recommended daridorexant 25 mg/d primarily for insomnia characterized by difficulty maintaining sleep and insufficient sleep duration, not specifically for sleep onset.
The Trade-off: Efficacy vs. Tolerability
The indirect comparison reveals an important clinical consideration: lemborexant shows an efficacy advantage while daridorexant demonstrates a tolerability advantage 2. Specifically:
- Lemborexant had higher rates of treatment-emergent adverse events, particularly somnolence, though discontinuation rates due to adverse events remained low 2, 5
- Daridorexant showed a more favorable safety profile with lower rates of somnolence and fatigue 2, though the 25 mg dose may increase risk of adverse events of special interest 3
Clinical Decision Algorithm
For patients whose primary complaint is difficulty falling asleep:
- First choice: Lemborexant 5-10 mg - strongest evidence for sleep onset improvement
- Consider daridorexant 50 mg if tolerability concerns exist with lemborexant
For patients with mixed sleep onset and maintenance problems:
- Lemborexant 10 mg offers broader coverage
- Daridorexant 25-50 mg if next-day somnolence is a concern
For elderly patients (≥65 years):
- Both agents are effective, but lemborexant and suvorexant showed higher rates of treatment-emergent adverse events compared to daridorexant in this population 5
- Consider starting with lower doses and monitoring for falls risk, as somnolence increases with age 6
Important Caveats
No FDA-approved guidelines exist specifically comparing these agents. The 2017 AASM guidelines predate both daridorexant (FDA approved 2022) and lemborexant (FDA approved 2019), only addressing the earlier DORA suvorexant 7. The 2016 ACP guideline similarly only evaluated suvorexant among DORAs 8.
All comparisons rely on indirect evidence through network meta-analyses, which have inherent limitations compared to direct head-to-head trials. The studies used different measurement tools and timepoints, making precise comparisons challenging.
The clinical significance of differences may be modest. While lemborexant shows statistical superiority for sleep onset, the absolute differences in minutes to fall asleep may not always translate to meaningful patient-reported improvements in quality of life.